| Primary |
| Prophylaxis |
31.3% |
| Oral Candidiasis |
18.8% |
| Candidiasis |
10.7% |
| Fungal Infection |
8.0% |
| Oral Fungal Infection |
5.4% |
| Systemic Mycosis |
5.4% |
| Vaginal Infection |
3.6% |
| Gastrointestinal Candidiasis |
2.7% |
| Dry Mouth |
1.8% |
| Gingival Bleeding |
1.8% |
| Oesophageal Candidiasis |
1.8% |
| Vulvovaginitis |
1.8% |
| Accidental Exposure |
0.9% |
| Accidental Exposure To Product |
0.9% |
| Alpha Haemolytic Streptococcal Infection |
0.9% |
| Blood Cholesterol |
0.9% |
| Blood Cholesterol Increased |
0.9% |
| Decubitus Ulcer |
0.9% |
| Dermatitis Diaper |
0.9% |
| Embolism Venous |
0.9% |
|
| Sepsis Neonatal |
31.3% |
| Candidiasis |
7.2% |
| Medication Error |
6.0% |
| Vomiting |
6.0% |
| Necrotising Enterocolitis Neonatal |
4.8% |
| Pregnancy |
4.8% |
| Rash |
4.8% |
| Drug Ineffective |
3.6% |
| Necrotising Colitis |
3.6% |
| Throat Irritation |
3.6% |
| Angioedema |
2.4% |
| Discomfort |
2.4% |
| Erythema |
2.4% |
| Hypersensitivity |
2.4% |
| International Normalised Ratio Increased |
2.4% |
| Oedema Peripheral |
2.4% |
| Oral Pain |
2.4% |
| Pruritus |
2.4% |
| Rash Pruritic |
2.4% |
| Swelling Face |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
25.3% |
| Foetal Exposure During Pregnancy |
19.6% |
| Tracheobronchitis |
6.2% |
| Oral Candidiasis |
5.0% |
| Fusarium Infection |
4.5% |
| Drug Use For Unknown Indication |
4.2% |
| Oropharyngeal Pain |
4.0% |
| Breast Cancer |
3.7% |
| Chronic Obstructive Pulmonary Disease |
3.7% |
| Lyme Disease |
3.7% |
| Fungal Infection |
3.0% |
| Hypertension |
2.7% |
| Oral Fungal Infection |
2.2% |
| Prophylaxis Against Transplant Rejection |
2.2% |
| Pseudomonas Infection |
2.0% |
| Asthma |
1.7% |
| Sleep Disorder |
1.7% |
| Caesarean Section |
1.5% |
| Colitis Ulcerative |
1.5% |
| Diabetes Mellitus Non-insulin-dependent |
1.5% |
|
| Medication Error |
14.3% |
| Drug Hypersensitivity |
7.1% |
| Lobar Pneumonia |
7.1% |
| Respiratory Arrest |
5.7% |
| Skin Exfoliation |
5.7% |
| Somnolence |
5.7% |
| Stevens-johnson Syndrome |
5.7% |
| Chronic Obstructive Pulmonary Disease |
4.3% |
| Hypersensitivity |
4.3% |
| Liver Injury |
4.3% |
| Oedema Peripheral |
4.3% |
| Pneumonia |
4.3% |
| Renal Failure Acute |
4.3% |
| Urticaria |
4.3% |
| Vomiting |
4.3% |
| Febrile Neutropenia |
2.9% |
| Hepatocellular Injury |
2.9% |
| Liver Disorder |
2.9% |
| Muscular Weakness |
2.9% |
| Oral Pain |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.6% |
| Drug Use For Unknown Indication |
21.1% |
| Pain |
4.6% |
| Prophylaxis |
4.4% |
| Nausea |
3.0% |
| Hypertension |
2.9% |
| Multiple Myeloma |
2.0% |
| Constipation |
2.0% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Depression |
1.7% |
| Anxiety |
1.7% |
| Hiv Infection |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.6% |
| Asthma |
1.5% |
| Crohn's Disease |
1.4% |
| Breast Cancer |
1.3% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Diffuse Large B-cell Lymphoma |
1.3% |
| Acute Myeloid Leukaemia |
1.2% |
| Non-small Cell Lung Cancer |
1.1% |
|
| Vomiting |
17.1% |
| Weight Decreased |
11.1% |
| Urinary Tract Infection |
6.1% |
| Pyrexia |
5.3% |
| Renal Failure Acute |
5.3% |
| Sepsis |
5.3% |
| Death |
5.0% |
| Thrombocytopenia |
5.0% |
| Weight Increased |
4.8% |
| Pneumonia |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Pain |
3.7% |
| Wheezing |
3.4% |
| Pulmonary Embolism |
2.9% |
| Respiratory Failure |
2.7% |
| Renal Failure |
2.7% |
| Vision Blurred |
2.7% |
| Stomatitis |
2.6% |
| Wound Infection Staphylococcal |
2.5% |
| Neutropenia |
2.4% |
|
| Interacting |
| Candida Infection |
36.4% |
| Gastrointestinal Stromal Tumour |
27.3% |
| Dyslipidaemia |
9.1% |
| Fungal Infection |
9.1% |
| Gastrooesophageal Reflux Disease |
9.1% |
| Multiple Allergies |
9.1% |
|
| Drug Level Decreased |
50.0% |
| Erythema |
16.7% |
| International Normalised Ratio Increased |
16.7% |
| Pruritus |
16.7% |
|
